^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Urothelial Cancer

    Related cancers:
    2d
    Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Dana-Farber Cancer Institute | Trial completion date: May 2030 --> Jul 2031 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    CIML NK
    2d
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=204, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    2d
    BLC2001: An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer (clinicaltrials.gov)
    P2, N=239, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Mar 2027
    Trial completion date
    |
    Balversa (erdafitinib) • metformin • midazolam hydrochloride
    2d
    FX-909-CLINPRO-1: A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=120, Recruiting, Flare Therapeutics Inc. | N=75 --> 120 | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Sep 2026 --> Oct 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CD4 (CD4 Molecule) • PPARG (Peroxisome Proliferator Activated Receptor Gamma)
    |
    Keytruda (pembrolizumab) • FX-909
    3d
    Combining Radiation therapy and Systemic Therapy in Advanced Urothelial Carcinoma: A Prospective Real-World Study. (ChiCTR2600117459)
    P=N/A, N=80, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    3d
    Development of a Multi-modal Deep Learning Model Integrating Imaging, Clinical, and Molecular Data for Preoperative Diagnosis and Pathologic Risk Prediction in Upper Tract Urothelial Carcinoma (ChiCTR2600117275)
    P=N/A, N=500, Not yet recruiting, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital
    New trial
    3d
    Study on the Molecular Characteristics and Spatiotemporal Evolution of Urothelial Carcinoma Based on Multi-omics Integration (ChiCTR2600116345)
    P=N/A, N=200, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    3d
    Automated Urine Detection of Urothelial Carcinoma Based on Coherent Raman Technology (ChiCTR2600116133)
    P=N/A, N=0, Recruiting, Peking University First Hospital; Peking University First Hospital
    New trial
    3d
    Maintenance Therapy with Tislelizumab after Postoperative Chemotherapy in Upper Tract Urothelial Carcinoma (ChiCTR2500115259)
    P=N/A, N=54, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    Tevimbra (tislelizumab-jsgr)
    3d
    Development and Clinical Validation of a Non-invasive Diagnostic Technique for Urothelial Carcinoma Based on Urinary DNA Methylation (ChiCTR2500114330)
    P=N/A, N=0, Recruiting, Shanghai General Hospital; Shanghai General Hospital
    New trial
    3d
    Safety Study of the Combination Regimen Based on HuA21 Monoclonal Antibody for the Treatment of Advanced HER2-overexpressing Solid Tumors (ChiCTR2500112039)
    P=N/A, N=90, Not yet recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel
    3d
    Human BHLHE40-ARL8B Gene Methylation Detection Kit (Fluorescent PCR Method) (ChiCTR2500113280)
    P=N/A, N=912, Completed, Renji Hospital, Shanghai Jiao Tong University School of Medicine; Suzhou Rendong Bioengineering Co., Ltd.
    New trial